Mannucci E, Gallo M, Pintaudi B, et al. - Due to insufficient evidence of beneficial or detrimental impacts of alpha-glucosidase inhibitors (approved drugs for type 2 diabetes) on all-cause mortality and cardiovascular events, it is not possible to draw conclusions.

• The impacts of alpha-glucosidase inhibitors on mortality and cardiovascular safety are unclear.

• This meta-analysis included a total of eight randomized controlled trials (of a duration ≥52 weeks), including 1,124 and 908 patients receiving alpha-glucosidase inhibitors and comparators, respectively.

• No trials provided information regarding major cardiovascular events.

• No significant increase in all-cause mortality was observed with alpha-glucosidase inhibitors vs other therapies or no therapy/placebo (Mantel-Haenszel odds ratio 0.58 [0.23, 1.45]).